Astellas Pharma Inc.'s Fiscal Year is From April To March - All Figures are in JPY, Trillions.
The item "Total-Revenue" stands at 2.01 Trillion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Astellas Pharma Inc.'s second quarter result of 0.5243 Trillion JPY for the item "Total Revenue" represents an increase of 3.66 percent compared to it's first quarter result.
Also, Astellas Pharma Inc.'s second quarter result of 0.5243 Trillion JPY for the item "Total Revenue" represents an increase of 13.37 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Astellas Pharma Inc.'s second quarter result of 2.01 Trillion JPY for the item "Total Revenue" represents an increase of 3.18 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 13.24 percent compared to the value the year prior.
The 1 year change in percent is 13.24.
The 3 year change in percent is 42.66.
The 5 year change in percent is 58.53.
The 10 year change in percent is 49.73.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Total Revenue | 905,699,262,464.00 |
![]() | Johnson & Johnson - Total Revenue | 486,508,953,600.00 |
![]() | AbbVie Inc - Total Revenue | 399,570,305,024.00 |
![]() | Roche Holding AG - Total Revenue | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Total Revenue | 280,205,508,085.11 |